@Article{, title={Serum hepcidin levels related to interlukin‑6 in patients with acute myeloid leukemia before and after treatment}, author={Dr. Alaadin Sahham Naji}, journal={Iraq Joural of Hematology المجلة العراقية لامراض الدم}, volume={11}, number={1}, pages={76-82}, year={2022}, abstract={BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous malignant disease ofhematopoietic tissue. It is characterized by accumulation of abnormal blast cells mainly in bonemarrow. Hepcidin is a small bioactive peptide hormone produced in many tissues mainly by theliver, macrophage, and adipocyte and it has been proposed as a marker of inflammation. The aimsof study were to assess the changes in serum levels of hepcidin, interleukin‑6, and ferritin in additionto iron‑binding capacity levels in patients with AML before and after chemotherapy treatment and tocompare their levels to healthy controls.MATERIALS AND METHODS: This study includes 43 AML patients (24 males and 19 females).They were divided into two groups: Group 1: Patients with AML before starting chemotherapy andGroup 2: after chemotherapy. The protocol used was (3 + 7) where doxorubicin was given from day1 to day 3 and Cytarabine (Ara‑C) was given from day 1 to day 7 then evaluation is done on 28th dayto evaluate response of patients. The control group (Group 3) included 43 healthy controls (24 malesand 19 females) who were matched with patients group in gender and age.RESULTS: Serum samples were investigated before and after treatment and compared with itscorresponding data of healthy control group and then statistically analyzed. Results revealed that:the prevalence of AML was higher in males than in females. Hepcidin levels were significantlyhigher in serum of (AML) patients (Group 2) compared to newly diagnosed (Group 1) and to healthycontrols (P < 0.0001). Serum (interleukin‑6) levels were higher but not statistically significantin (Group 1) when compared to (Group 2) while it was statistically significantly when compared tohealthy controls (P < 0.214 and P < 0.0001, respectively). Regarding serum levels of ferritin and totaliron capacity (TIBC) predicted highly significant increase for all patients when compared to controls.CONCLUSION: Hepcidin and interleukin‑6 may be used as diagnostic criteria for treatment responseof AML and also can utilized as biomarkers for the progression of the AML

} }